Subclinical Hypothyroidism after a Three-Month Course of Low-Dose Amiodarone.

Rano Kirkimbayeva 1 * , Telman Seisembekov 1, Bakyt Iskakova 1, Nauryzbay Bekishuly 2, Assel Chinybayeva 1, Galiya Smailova 1, Diana Aibulova 1, Aya Aitpayeva 1, Aidana Butabayeva 1, Zhansaya Yerkhanova 2, Olzhas Yesseneyev 1, Ayan Abdrakhmanov 1 2
More Detail
1 Department of Cardiology, Astana Medical University, Astana, Kazakhstan
2 Department of Arrhytmology, Medical Centre Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, In press. https://doi.org/10.23950/jcmk/16204
OPEN ACCESS 76 Views 0 Downloads
Author Contributions:  Conceptualization, R. K., A. A., B. I., T. S.; methodology, A. A., B. I., T. S.; validation, R. K., A. A., Z. Y.; formal analysis, A. A., N. B.; investigation, AB, R. K., OY; resources, AC, GS; data curation, A. C., G. S., N. B.; writing – original draft preparation, R. K., A. A., Z. Y.; writing – review and editing, R. K., N. B., D. A.; visualization, Z. Y., N. B.; supervision: A. A., T. S., B. I.; project administration, R. K.; funding acquisition, Not applicable. All authors have read and agreed to the published version of the manuscript.

ABSTRACT

This case report describes a 64-year-old male who developed subclinical hypothyroidism after three months of low-dose amiodarone (100 mg/day). Routine monitoring showed a TSH increase to 44.40 mU/L with normal FT4 and FT3 levels. Based on the Naranjo scale (score: 7), amiodarone was deemed a probable cause of SCH. This case highlights the importance of routine thyroid monitoring during amiodarone therapy, even at low doses.
Keywords: Side effects of amiodarone, amiodarone induced subclinical hypothyroidism, low dose of amiodarone, ablation, cryobaloon isolation, atrial fibrillation.

CITATION

Kirkimbayeva R, Seisembekov T, Iskakova B, Bekishuly N, Chinybayeva A, Smailova G, et al. Subclinical Hypothyroidism after a Three-Month Course of Low-Dose Amiodarone.. J Clin Med Kaz. 2025. https://doi.org/10.23950/jcmk/16204

REFERENCES

  • Medić F, Bakula M, Alfirević M, Bakula M, Mucić K, Marić N. Amiodarone and thyroid dysfunction. Acta Clin Croat. 2022; 61(2): 327–341. https://doi.org/10.20471/acc.2022.61.02.20
  • Zhong B, Wang Y, Li H, Zhang G, Wang G. Environmental Iodine Content, Female Sex and Age Are Associated with New-Onset Amiodarone-Induced Hypothyroidism: A Systematic Review and Meta-Analysis of Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016; 134(3): 366–371. https://doi.org/10.1159/000444578.
  • Mohammadi K, Shafie D, Vakhshoori M, Bondariyan N, Rezvanian H, Heidarpour M. Prevalence of Amiodarone Induced Hypothyroidism and Hyperthyroidism in Patients with Heart Diseases: A Systematic Review and Meta-Analysis. Trends Cardiovasc Medicine. 2023; 33(4): 252–262. https://doi.org/10.1016/j.tcm.2022.01.001
  • Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal. 2018; 7: 55–66. https://doi.org/10.1159/000486957
  • Naranjo adverse drug reaction probability scale. Available at: https://www.evidencio.com/models/show/661
  • Hamid I, Farooq I, Bashir H, Hayat Bhat M, Majid S. Current Insights into the Diagnosis and Management of Subclinical Hypothyroidism: A Systematic Review. International Journal of Life Sciences, Biotechnology and Pharma Research. 2024; 13(8): 59. https://doi.org/10.69605/ijlbpr_13.8.2024.59
  • Ku EJ, Yoo WS, Chung HK. Management of subclinical hypothyroidism: a focus on proven health effects in the 2023 Korean Thyroid Association guidelines. Endocrinol Metab (Seoul). 2023; 38(4): 381–391. https://doi.org/10.3803/EnM.2023.1778